ALLO
Allogene Therapeutics, Inc.
Healthcare · Biotechnology · NMS
$1.88
Data: 2026-05-15
✓ ETHICAL PASS

MOAT
MODERATE
Data Confidence: 57.1%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$695M
Total market value of the company
Trailing P/E
N/A
Forward P/E
-2.51
Based on estimated future earnings — lower means cheaper
Rev Growth
N/A
Year-over-year revenue change
Profit Margin
N/A
How much profit the company keeps from each dollar of revenue
ROE
-52.3%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$8.35
+344% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 11 analysts covering this stock
About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

https://allogene.com

Country: United States Employees: 150 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
10.6% PASS
Debt must be below 33% of total assets
Cash Ratio
31.9% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKDOWN
Price trending down — defensive positioning
Sharpe Ratio
0.390
Positive but modest risk-adjusted returns
Kelly Fraction
-0.0242
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.091
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-6.7%
Historical annualised return based on price data
Max Drawdown
-72.9%
Largest peak-to-trough decline — the worst it has been
HMM State
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
9
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
0.46
Very low correlation to market moves
52W High
$4.46
58% below the year high
52W Low
$0.98
92% above the year low
Avg Volume
9,566,272
Average daily shares traded — higher means easier to buy and sell
Short Ratio
2.4
Days it would take all short sellers to cover — higher means more crowded
Short % Float
11.8%
Elevated short interest — bears are positioned against this
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-0.87
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.29
Conservative use of debt — low financial risk
Current Ratio
9.65
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
9.47
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Free Cash Flow
$-69,944,872
Negative — the business is spending more than it generates
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
$-173,760,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
11
Target High
$14.00
Target Median
$8.35
Target Low
$3.85
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-04-21 YOSHIYAMA ANNIE Officer 9,586 $22,144
2026-03-31 BENESKI BENJAMIN MACHINAS Chief Technology Officer 2,867 $7,168
2026-03-16 CHANG DAVID D Chief Executive Officer 47,763 $117,975
2026-03-16 BENESKI BENJAMIN MACHINAS Chief Technology Officer 4,835 $11,942
2026-03-02 BENESKI BENJAMIN MACHINAS Chief Technology Officer 7,132 $18,543
2026-02-02 DOUGLAS EARL MARTIN General Counsel 22,900 $40,304
2026-02-02 CHANG DAVID D Chief Executive Officer 95,269 $171,484
2026-02-02 PARKER GEOFFREY M Chief Financial Officer 24,001 $42,242
2026-02-02 YOSHIYAMA ANNIE Officer 4,167 $7,167
2026-02-02 ROBERTS ZACHARY Officer 35,700 $63,189
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.